Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
life sciences
national blog main
8
×
biotech
boston blog main
fda
boston top stories
boston
san diego blog main
san francisco blog main
new york blog main
san diego top stories
deals
detroit blog main
detroit top stories
drugs
dyne therapeutics
investing
myotonic dystrophy type 1
national top stories
new enterprise associates
rare disease drugs
achaogen
adams street partners
aimmune therapeutics
akouos
aldehyde
aldeyra therapeutics
allergic conjunctivitis
allergy
anaphylaxis
andrew oxtoby
antibiotics
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
bempedoic acid
beta lactamase inhibitor
What
drug
8
×
therapeutics
8
×
medicines
fda
ipo
approved
company
data
developing
dyne
fighting
genetic
muscle
new
phase
rare
treat
affects
agency
ago
aimmune
aldeyra
allergy
americans
approval
awarded
bacteria
biopharma
biotech
biotechs
black
brings
business
cancer
cholesterol
clinic
closer
combo
companies
considering
Language
unset
Current search:
drug
×
" national blog main "
×
therapeutics
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections